Emulation of the RECORD3 Trial Using Healthcare Claims Data
NCT07599384 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 149248
Last updated 2026-05-20
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Deep Vein Thrombosis, Pulmonary Embolus
Interventions
- DRUG
-
Rivaroxaban
Initiation of rivaroxaban described in electronic health records is used as the exposure.
- DRUG
-
Enoxaparin
Initiation of enoxaparin described in electronic health records is used as the reference.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-13
- Primary Completion
- 2026-06-01
- Completion
- 2026-06-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data
NCT04593056 ·Status: COMPLETED
-
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
NCT05256797 ·Status: COMPLETED
-
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
NCT02064439 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
NCT00521885 ·Status: TERMINATED ·Phase: NA
-
Validation of Predictors of OAC Initiation Using EMR Data
NCT03006341 ·Status: COMPLETED
-
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
NCT02584660 ·Status: COMPLETED ·Phase: PHASE4
-
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
NCT02506985 ·Status: TERMINATED ·Phase: PHASE4
-
BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
NCT03613402 ·Status: WITHDRAWN
-
Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries
NCT02339818 ·Status: COMPLETED
-
Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism
NCT03091621 ·Status: UNKNOWN
-
ARIXTRA® Adherence in SVT Patients.
NCT01691495 ·Status: COMPLETED
-
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
NCT03266783 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
NCT00443053 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
NCT02833948 ·Status: COMPLETED ·Phase: PHASE3
-
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
NCT02769078 ·Status: COMPLETED
-
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
NCT02559856 ·Status: COMPLETED ·Phase: PHASE4
-
Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
NCT03158792 ·Status: COMPLETED ·Phase: PHASE4
-
Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
NCT02345343 ·Status: COMPLETED
-
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
NCT00633893 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Rivaroxaban for CeREbral Venous Thrombosis
NCT03178864 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
NCT00440193 ·Status: COMPLETED ·Phase: PHASE3
-
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
NCT01776424 ·Status: COMPLETED ·Phase: PHASE3
-
LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin
NCT00321009 ·Status: COMPLETED ·Phase: NA
-
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
NCT03404635 ·Status: COMPLETED